More Health Insurance Companies May Soon Cover the GLP-1 Obesity Drugs Zepbound and Foundayo 

Staff
By Staff
4 Min Read

GLP-1 medications can deliver significant weight loss results, but high price tags can make them difficult for many to access or stay on — often because of inconsistent or nonexistent insurance coverage.

Today, Eli Lilly has announced a plan to increase access and affordability for its GLP-1 obesity treatments, Zepbound (tirzepatide) and Foundayo (orforglipron): “All three of the nation’s largest pharmacy benefit managers (PBMs) will cover Lilly’s full obesity medicine portfolio,” the company said in a statement. It also announced that Medicare Part D coverage will be expanding.

These changes should effectively increase the number of Americans who can access these medications through their existing health insurance.

“This is a significant development for obesity treatment access,” says Christine Bonarrigo, PharmD, a clinical pharmacist at Tufts Medical Center in Boston. “It also signals that obesity care is continuing to move into the healthcare mainstream, rather than being treated as optional or cosmetic.”

Read the full article here

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *